BRIUMVI competes in the $20B+ MS market against Roche's Ocrevus ($7B) and Novartis's Kesimpta. Differentiated by glycoengineered anti-CD20 design and shorter infusion time. Profitable at 18.6x P/E with 83.6% gross margins.
Conviction●●●○○3 of 5
Research target—Snapshot target
Thesis statusACTIVE_RESEARCHLast reviewed Not reviewed
Market cap$8.16BSnapshot value
BRIUMVI MS market share gains, BRIUMVI label expansion (primary progressive MS, pediatric), pipeline data in autoimmune/oncology, quarterly revenue beats vs consensus
1. BRIUMVI MS share stalls — Ocrevus/Kesimpta dominance unshaken. 2. Roche launches subcutaneous Ocrevus — eliminates BRIUMVI's convenience advantage. 3. CD20 class safety signal (infection, malignancy). 4. Generic rituximab off-label erosion. 5. Single-product risk — no pipeline buffer.
Elevated retail interest driven by BRIUMVI growth narrative and squeeze potential. Very high short ratio (15.3) attracts meme/squeeze attention.
Snapshot · Not reviewedNo positioning snapshot available.
Snapshot · Not reviewed